A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

NCT02631876 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
366
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

ImmunoGen, Inc.

Collaborators